TY - JOUR
T1 - Repurposing molecular imaging and sensing for cancer image-guided surgery
AU - Mondal, Suman B.
AU - O'Brien, Christine M.
AU - Bishop, Kevin
AU - Fields, Ryan C.
AU - Margenthaler, Julie A.
AU - Achilefu, Samuel
N1 - Publisher Copyright:
© 2020 Society of Nuclear Medicine Inc.. All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Gone are the days when medical imaging was used primarily to visualize anatomic structures. The emergence of molecular imaging (MI), championed by radiolabeled 18F-FDG PET, has expanded the information content derived from imaging to include pathophysiologic and molecular processes. Cancer imaging, in particular, has leveraged advances in MI agents and technology to improve the accuracy of tumor detection, interrogate tumor heterogeneity, monitor treatment response, focus surgical resection, and enable image-guided biopsy. Surgeons are actively latching on to the incredible opportunities provided by medical imaging for preoperative planning, intraoperative guidance, and postoperative monitoring. From label-free techniques to enabling cancer-selective imaging agents, imageguided surgery provides surgical oncologists and interventional radiologists both macroscopic and microscopic views of cancer in the operating room. This review highlights the current state of MI and sensing approaches available for surgical guidance. Salient features of nuclear, optical, and multimodal approaches will be discussed, including their strengths, limitations, and clinical applications. To address the increasing complexity and diversity of methods available today, this review provides a framework to identify a contrast mechanism, suitable modality, and device. Emerging low-cost, portable, and user-friendly imaging systems make the case for adopting some of these technologies as the global standard of care in surgical practice.
AB - Gone are the days when medical imaging was used primarily to visualize anatomic structures. The emergence of molecular imaging (MI), championed by radiolabeled 18F-FDG PET, has expanded the information content derived from imaging to include pathophysiologic and molecular processes. Cancer imaging, in particular, has leveraged advances in MI agents and technology to improve the accuracy of tumor detection, interrogate tumor heterogeneity, monitor treatment response, focus surgical resection, and enable image-guided biopsy. Surgeons are actively latching on to the incredible opportunities provided by medical imaging for preoperative planning, intraoperative guidance, and postoperative monitoring. From label-free techniques to enabling cancer-selective imaging agents, imageguided surgery provides surgical oncologists and interventional radiologists both macroscopic and microscopic views of cancer in the operating room. This review highlights the current state of MI and sensing approaches available for surgical guidance. Salient features of nuclear, optical, and multimodal approaches will be discussed, including their strengths, limitations, and clinical applications. To address the increasing complexity and diversity of methods available today, this review provides a framework to identify a contrast mechanism, suitable modality, and device. Emerging low-cost, portable, and user-friendly imaging systems make the case for adopting some of these technologies as the global standard of care in surgical practice.
KW - Cerenkov luminescence
KW - Fluorescence imaging
KW - Molecular image-guided surgery
KW - Multimodal imaging
KW - Nuclear imaging
KW - Research methods
UR - http://www.scopus.com/inward/record.url?scp=85089126615&partnerID=8YFLogxK
U2 - 10.2967/jnumed.118.220426
DO - 10.2967/jnumed.118.220426
M3 - Review article
C2 - 32303598
AN - SCOPUS:85089126615
SN - 0161-5505
VL - 61
SP - 1113
EP - 1122
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 8
ER -